{"id":742120,"date":"2011-05-16T10:30:00","date_gmt":"2011-05-16T10:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\/"},"modified":"2026-08-10T13:01:18","modified_gmt":"2026-08-10T17:01:18","slug":"merck-completes-acquisition-of-inspire-pharmaceuticals-inc","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\/","title":{"rendered":"Merck Completes Acquisition of Inspire Pharmaceuticals, Inc."},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that it is has completed its acquisition of Inspire<br \/>\n      Pharmaceuticals, Inc., a specialty pharmaceutical company focused on<br \/>\n      developing and commercializing ophthalmic products, for $5.00 per share<br \/>\n      in cash.\n    <\/p>\n<p>\n      \u201cWe are excited to complete this compelling and highly complementary<br \/>\n      acquisition of Inspire,\u201d said Beverly Lybrand, senior vice president and<br \/>\n      general manager, neuroscience and ophthalmology, Merck. \u201cThe successful<br \/>\n      completion of this transaction strengthens our ophthalmology business<br \/>\n      and positions us for future growth with an expanded portfolio and a best<br \/>\n      in class commercialization organization.\u201d\n    <\/p>\n<p>\n      Effective today, Monarch Transaction Corp. a wholly-owned subsidiary of<br \/>\n      Merck, has merged with and into Inspire, with Inspire surviving as a<br \/>\n      wholly owned subsidiary of Merck. As a result of the merger, Inspire<br \/>\n      shares have ceased trading on the NASDAQ Global Market and Inspire will<br \/>\n      no longer have reporting obligations under the Securities and Exchange<br \/>\n      Act of 1934, as amended.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2F&amp;esheet=50287861&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=1&amp;md5=579a17d959a9ea3e1bcb5731f7ce6759\">www.merck.com<\/a>.\n    <\/p>\n<p>\n      <b>Forward-looking statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company\u2019s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck\u2019s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that the expected synergies from the merger of Merck and<br \/>\n      Schering-Plough will not be realized, or will not be realized within the<br \/>\n      expected time period; the impact of pharmaceutical industry regulation<br \/>\n      and health care legislation; the risk that the businesses will not be<br \/>\n      integrated successfully; disruption from the merger making it more<br \/>\n      difficult to maintain business and operational relationships; Merck\u2019s<br \/>\n      ability to accurately predict future market conditions; dependence on<br \/>\n      the effectiveness of Merck\u2019s patents and other protections for<br \/>\n      innovative products; the risk of new and changing regulation and health<br \/>\n      policies in the United States and internationally and the exposure to<br \/>\n      litigation and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2010 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=50287861&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=b255f0c6d262d3c7879b0c0abbffc0d2\">www.sec.gov<\/a>).\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120523005739r1&amp;sid=sfsite1&amp;distro=nx\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p>       Merck<br \/>Media Contact:<br \/>Ian McConnell, 908-423-3046<br \/>or<br \/>Investor        Contact:<br \/>Carol Ferguson, 908-423-4465     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it is has completed its acquisition of Inspire Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing ophthalmic products, for $5.00 per share in cash. \u201cWe are excited to complete this compelling and highly complementary acquisition of Inspire,\u201d said Beverly Lybrand, senior vice president and general manager, neuroscience and ophthalmology, Merck. \u201cThe successful completion of this transaction strengthens our ophthalmology business and positions us for future growth with an expanded portfolio and a best in class commercialization organization.\u201d Effective today, Monarch Transaction Corp. a wholly-owned subsidiary of Merck, has merged with and into Inspire, with Inspire surviving as a wholly owned subsidiary of Merck. As a result of the merger, Inspire shares have ceased trading on the NASDAQ Global Market and Inspire will no longer have reporting<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742120","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Completes Acquisition of Inspire Pharmaceuticals, Inc. - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Completes Acquisition of Inspire Pharmaceuticals, Inc. - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it is has completed its acquisition of Inspire Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing ophthalmic products, for $5.00 per share in cash. \u201cWe are excited to complete this compelling and highly complementary acquisition of Inspire,\u201d said Beverly Lybrand, senior vice president and general manager, neuroscience and ophthalmology, Merck. \u201cThe successful completion of this transaction strengthens our ophthalmology business and positions us for future growth with an expanded portfolio and a best in class commercialization organization.\u201d Effective today, Monarch Transaction Corp. a wholly-owned subsidiary of Merck, has merged with and into Inspire, with Inspire surviving as a wholly owned subsidiary of Merck. As a result of the merger, Inspire shares have ceased trading on the NASDAQ Global Market and Inspire will no longer have reporting\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:18+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20120523005739r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\\\/\",\"name\":\"Merck Completes Acquisition of Inspire Pharmaceuticals, Inc. - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120523005739r1&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2011-05-16T10:30:00+00:00\",\"dateModified\":\"2026-08-10T17:01:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120523005739r1&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120523005739r1&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Completes Acquisition of Inspire Pharmaceuticals, Inc.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Completes Acquisition of Inspire Pharmaceuticals, Inc. - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\/","og_locale":"en_US","og_type":"article","og_title":"Merck Completes Acquisition of Inspire Pharmaceuticals, Inc. - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it is has completed its acquisition of Inspire Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing ophthalmic products, for $5.00 per share in cash. \u201cWe are excited to complete this compelling and highly complementary acquisition of Inspire,\u201d said Beverly Lybrand, senior vice president and general manager, neuroscience and ophthalmology, Merck. \u201cThe successful completion of this transaction strengthens our ophthalmology business and positions us for future growth with an expanded portfolio and a best in class commercialization organization.\u201d Effective today, Monarch Transaction Corp. a wholly-owned subsidiary of Merck, has merged with and into Inspire, with Inspire surviving as a wholly owned subsidiary of Merck. As a result of the merger, Inspire shares have ceased trading on the NASDAQ Global Market and Inspire will no longer have reporting","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:18+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20120523005739r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\/","name":"Merck Completes Acquisition of Inspire Pharmaceuticals, Inc. - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120523005739r1&amp;sid=sfsite1&amp;distro=nx","datePublished":"2011-05-16T10:30:00+00:00","dateModified":"2026-08-10T17:01:18+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120523005739r1&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120523005739r1&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-completes-acquisition-of-inspire-pharmaceuticals-inc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Completes Acquisition of Inspire Pharmaceuticals, Inc."}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"9cd233f3-0b26-4a53-bafc-8b80c0e84712","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742120\/revisions"}],"predecessor-version":[{"id":3679256,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742120\/revisions\/3679256"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742120"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}